Eterna Therapeutics Inc. (NTN) [Rocket]

Overview

Eterna Therapeutics Inc. (NTN)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/05/2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
09/26/2023	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/25/2023	4	Cherington Charles (10% Owner) has filed a Form 4 on Eterna Therapeutics Inc.
08/23/2023	424B3	Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/23/2023	EFFECT	Form EFFECT - Notice of Effectiveness:
08/14/2023	S-3	Form S-3 - Registration statement under Securities Act of 1933:
08/11/2023	10-Q	Quarterly Report for the period ended June 30, 2023

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	0.0	0.0	0.0	19.8	23.3	28.0	22.3	24.5
Revenue growth			-100.0%	-15.1%	-16.7%	25.6%	-9.0%	-5.9%
Cost of goods sold	0.0	0.0	0.0	7.5	8.1	6.8	7.7	12.6
Gross profit	0.0	0.0	0.0	12.3	15.3	21.3	14.6	11.9
Gross margin				62.2%	65.4%	75.9%	65.4%	48.7%
Selling, general and administrative				13.2	14.5	15.6	16.5	18.1
Research and development	10.4	12.7	4.0
General and administrative	16.8	14.7	3.3
EBITA	-27.2	-42.8	-7.2	-1.8	0.5	-1.4	-2.2	-6.8
EBITA margin				-8.9%	2.0%	-5.0%	-10.0%	-27.9%
Amortization of intangibles							0.1	0.1
EBIT	-27.2	-42.8	-7.2	-1.8	0.5	-1.4	-2.3	-6.9
EBIT margin				-8.9%	2.0%	-5.0%	-10.2%	-28.1%
Pre-tax income	-24.5	-122.5	-7.3	-2.0	-0.3	-1.0	-2.9	-7.2
Income taxes	0.0	0.1	0.0	0.0	-0.1	0.1	0.0	0.0
Tax rate			0.0%		19.8%
Net income	-24.6	-122.6	-7.3	-2.1	-0.3	-1.1	-2.9	-7.2
Net margin				-10.4%	-1.2%	-3.9%	-13.1%	-29.5%

Diluted EPS	($8.06)	($56.61)	($0.41)	($0.72)	($0.10)	($0.45)	($1.54)	($3.93)
Shares outstanding (diluted)	3.1	2.2	17.6	2.9	2.7	2.4	1.9	1.8

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.